EXPERIMENT WITH MEDICINES: Karl-Henning Kalland (left), Yi Qu and Xisong Ke have experimented with hundreds of substances on cancer. Photo: Kim E. Andreassen via: UiB
Medicine against parasites like Tapeworms and Giardia, contains a substance that kills Prostate- and colon cancer.
Cancer researchers at the University of Bergen (UiB) have in the recent years experienced with hundreds of known drugs, to see how they influence cancer cells.
Recently they found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.
“We discovered that this specific substance is blocking the signalling pathway in the cancer cells, and make them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one, ” says Professor Karl-Henning Kalland at the Department of Clinical Science, at UiB. He is the leader of the Kalland´s Research Group.
The study is published in Nature Chemical Biology.
Hyperactive cells
The researchers Yi Qu and Xisong Ke at Kalland team saw that the cells in prostate- and colon cancer contain high amounts of activated Beta-catenin. Activation of this protein makes the cells go amok and divides at high tempo. In addition, Beta-catenin makes the cancer cells more resistant and more able for survival.
In the study, Qu and Ke discovered that it was the substance NTZ (nitazoxanide), a well known and approved anti-parasite drug, that decompose the activated Beta-catenin.
“We are the first researchers who have mapped the complex molecular mechanisms involved in this process,” Kalland says.
Recycling old medicines
Experiments with well-known drugs show that a medicine may have different and unknown targets in the cells.
“The advantage of testing already approved drugs, is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker,” Kalland explains.
Strengthen the immune system
NTZ attacks cancer celles by hindering the activated Beta-catenin. It appears that this hindering also stimulates central parts of the immune system, that attacks cancer cells.
“At the moment, we are working on how to strengthen our on going immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ,” Kalland says.
Kalland and his research-team is in the first phase in a clinical trial using immune therapy against prostate cancer.
Learn more: Tapeworm drug fights Prostate Cancer
The Latest on: Immune therapy
- Immunotherapy startup Umoja lands $210M, less than a year after raising $53Mon June 18, 2021 at 10:49 am
Just seven months after announcing a $53 million Series A round, Umoja Biopharma has raised an additional $210 million in a Series B round. The company is developing ...
- Tumor Immunotherapy Market Is Slated To Grow Rapidly In The Coming Yearson June 18, 2021 at 8:16 am
The report titled Global Tumor Immunotherapy Market showcases an in-depth analysis of the overall Tumor Immunotherapy market in terms of market size, segmentation for Tumor Immunotherapy providers, ...
- Immunotherapy Options Around the Bendon June 18, 2021 at 6:00 am
One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year. Although immunotherapy has become a major pillar in cancer, the current generation of T-cell therapies ...
- Combination immunotherapy for advanced bowel cancer approved for NHS in Englandon June 17, 2021 at 6:50 am
People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England, following the approval of the ...
- Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Canceron June 17, 2021 at 5:00 am
In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial.
- Weight-based dosing strategy may affect immunotherapy outcomes, shows studyon June 14, 2021 at 9:52 pm
Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT ...
- More Study Needed on Benefits of Immunotherapy in Narcolepsyon June 14, 2021 at 1:45 pm
These review results show tested immunotherapies had mostly temporar were mixed on the use of immunotherapy to treat narcolepsy, with benefits typically being temporaryy benefits and that because a ...
- Study finds dosing strategy may affect immunotherapy outcomeson June 14, 2021 at 1:14 pm
Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT ...
- GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteoson June 14, 2021 at 4:00 am
With a TIGIT antibody in its possession, Glaxo may be in a better position to catch up to pharma rivals in cancer.
- Local hospital explains revolutionary CAR T-cell immunotherapy for cancer patientson June 13, 2021 at 8:53 pm
There’s a breakthrough therapy for treating patients with blood cancer called CAR T-cell immunotherapy. Dr. Paul Shaughnessy, medical director of the Adult Blood and Marrow STEM Cell Transplant ...
via Google News and Bing News
Go deeper with Bing News on:
Immune system
- Start-stop system of hunting immune cellson June 19, 2021 at 12:36 pm
Researchers decipher the basic biology of neutrophil swarming and now show that the cells also evolved an intrinsic molecular program to self-limit their swarming activity. The study elucidates how ...
- Ask the Doctors: Is there anything to ‘hygiene hypothesis’ tying cleanliness to immune system?on June 18, 2021 at 5:30 am
An array of so-called ‘friendly’ bacteria, fungi and viruses plays a part in keeping our bodies functioning properly.
- The Immune System’s Weirdest Weaponon June 17, 2021 at 10:48 am
For decades, neutrophils have been miscast as the immune system’s mindless grunts. They’re more like super-soldiers. Every drop of pus that’s squeezed out of the human body is a squidgy mess—a ...
- Infant Immune System Trained by Key Gut Bacteriaon June 17, 2021 at 8:36 am
Many diseases caused by a dysregulated immune system, such as allergies, asthma and autoimmunity, can be traced back to events in the first few months after birth, although the mechanisms were poorly ...
- First months decisive for immune system developmenton June 17, 2021 at 8:00 am
Many diseases caused by a dysregulated immune system, such as allergies, asthma and autoimmunity, can be traced back to events in the first few months after birth. To date, the mechanisms behind the ...
Go deeper with Google Headlines on:
Immune system
Go deeper with Bing News on:
Immune therapy
- Immunotherapy startup Umoja lands $210M, less than a year after raising $53Mon June 18, 2021 at 10:49 am
Just seven months after announcing a $53 million Series A round, Umoja Biopharma has raised an additional $210 million in a Series B round. The company is developing ...
- Tumor Immunotherapy Market Is Slated To Grow Rapidly In The Coming Yearson June 18, 2021 at 8:16 am
The report titled Global Tumor Immunotherapy Market showcases an in-depth analysis of the overall Tumor Immunotherapy market in terms of market size, segmentation for Tumor Immunotherapy providers, ...
- Immunotherapy Options Around the Bendon June 18, 2021 at 6:00 am
One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year. Although immunotherapy has become a major pillar in cancer, the current generation of T-cell therapies ...
- Combination immunotherapy for advanced bowel cancer approved for NHS in Englandon June 17, 2021 at 6:50 am
People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England, following the approval of the ...
- Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Canceron June 17, 2021 at 5:00 am
In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial.
